Phase 3 development will address two major unmet needs in patients who are poorly served by currently available therapies:
- Patients with risk factors for cardiovascular disease and those with cardiovascular disease
- Patients who have not had adequate response to triptans
Migraine is ranked as the seventh highest cause of global disability and in the top 10 causes of disability in 14 of 21 world regions studied, according to findings by the
Global Burden of Disease Survey 2010
conducted by the World Health Organization. It is the leading cause of disability among neurological disorders. Some 36 million Americans have migraine, more than have asthma or diabetes combined. Migraine can be extremely disabling and costly, accounting for more than
in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in
the United States
. The prevalence of migraine in
is approximately 9%, and in
alone, it is 6%. According to statistics available from the Health and Insurance Review Agency (HIRA), in 2012 more than 500,000 patients were diagnosed with migraine in Korea, with women accounting for 72% of these numbers.
ABOUT COLUCID PHARMACEUTICALS, INC.
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes Lasmiditan, a novel treatment for migraine headache. Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans. Lasmiditan is a member of a novel drug class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets receptors expressed in the trigeminal pathway. Lasmiditan does not interact with vasoconstrictor receptors on peripheral blood vessels which are activated by triptans. For more information, please visit CoLucid at
ABOUT ILDONG PHARMACEUTICAL CO., LTD.
ILDONG Pharmaceutical Co., Ltd., based in
, is a leading Korean company focused on the development, manufacturing and marketing of pharmaceuticals and OTC products with sales of
in 2012. ILDONG, founded in 1941, is known to have leading expertise in various therapeutic categories, including neurology, antibiotics, gastrointestinal, anti-diabetics, cardiovascular and oncology. For more information, visit ILDONG's website at
SOURCE CoLucid Pharmaceuticals, Inc; ILDONG Pharmaceutical Co., Ltd.